Data integrity failures trigger a global regulatory crackdown on clinical trial validity.
Exposing good clinical practice breaches and unblinded data manipulation leads to immediate peer-reviewed retractions and the revocation of established drug approvals.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
An investigation proving that endpoint assessments were altered post-database lock forced a major medical journal retraction and a proposed market withdrawal.
Allegations of unblinded data manipulation in the pivotal trial have triggered a formal proposal by the FDA to withdraw the drug from the market.
Europe's regulator moved to revoke the drug's approval due to severe GCP violations and manipulated clinical trial data.
Exposing post-unblinding data manipulation led to the peer-reviewed retraction of the drug's pivotal study and immediate regulatory efforts to revoke its marketing authorization.
The FDA initiated proceedings to strip Amgen's drug of its approval following discoveries of clinical trial database manipulation.
Undisclosed post-unblinding alterations to primary endpoints compromised trial integrity, triggering an official journal retraction and FDA proposal to withdraw the drug.
Regulatory agencies revoked marketing authorizations globally following the exposure of post-unblinding database manipulation in the drug's sole trial.
This exemplifies how national security concerns compel regulators to step in and retroactively force the legal dissolution of cross-border technological acquisitions.